SAP co-founder and football patron Dietmar Hopp has invested EUR 80 million in the Tübinger biotechnology firm CureVac, originally founded by young researchers in 2000.
CureVac developed a new type of medication on the basis of the so-called mRNA, especially for cancer patients. The aim is to supply the body artificial mRNA so that it produces proteins that may, for example, destroy cancer cells.
The market potential for this technology is „enormous“, explained Hopp’s Investment company, following their investment which was one of the largest in Europe in this industry for some years. The investment will be used primarily for the development of drugs against prostate and lung cancer, and infectious diseases. Hopp has invested in CureVac since 2006 – but it was always far smaller sums.
[ilink url=“http://www.kma-online.de/nachrichten/politik/id__28322___view.html“] Link zur Quelle (kma-online)[/ilink]